Crusia

Leaflet accompanying the packaging: patient information

Crusia, 2000 IU (20 mg)/0.2 ml, solution for injection in a pre-filled syringe
Crusia, 4000 IU (40 mg)/0.4 ml, solution for injection in a pre-filled syringe
Crusia, 6000 IU (60 mg)/0.6 ml, solution for injection in a pre-filled syringe
Crusia, 8000 IU (80 mg)/0.8 ml, solution for injection in a pre-filled syringe
Crusia, 10,000 IU (100 mg)/1 ml, solution for injection in a pre-filled syringe
This medicinal product is subject to additional monitoring. This will allow for quick identification of new safety information. You can help by reporting any side effects you may get. To find out how to report side effects, see section 4.
Enoxaparin sodium

You should carefully read the contents of this leaflet before using the medicine, as it contains important information for the patient.

• You should keep this leaflet, so you can read it again if you need to.
• If you have any further questions, you should ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed specifically for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, including those not listed in this leaflet, you should tell your doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Crusia and what is it used for
• 2. Important information before using Crusia
• 3. How to use Crusia
• 4. Possible side effects
• 5. How to store Crusia
• 6. Contents of the packaging and other information

1. What is Crusia and what is it used for

Crusia contains the active substance enoxaparin sodium, which is a low molecular weight heparin (LMWH).
Crusia works in two ways.

• 1) It prevents the growth of existing blood clots. This helps the body to dissolve existing blood clots, making them no longer harmful.
• 2) It prevents the formation of new blood clots in the patient's blood.

Crusia can be used for:

• Treating blood clots that are already present in the patient's blood.
• Preventing the formation of blood clots in the patient's blood in the following situations: before and after surgery, during acute illness when the patient has limited mobility, if the patient has had blood clots caused by cancer to prevent further clots, in unstable angina (a condition where the heart does not receive enough blood), after a heart attack
• Preventing the formation of clots in the dialyzer tubing (used in people with severe kidney function disorders).

in patients with severe kidney function disorders.

2. Important information before using Crusia

When not to use Crusia

• If the patient is allergic to enoxaparin sodium or any of the other ingredients of this medicine (listed in section 6). Symptoms of an allergic reaction may include: rash, difficulty swallowing or breathing, swelling of the mouth, face, throat, or tongue.
• If the patient has been diagnosed with an allergy to heparin or other low molecular weight heparins, such as nadroparin, tinzaparin, or dalteparin.
• If the patient has been diagnosed with a reaction to heparin that caused a significant decrease in the number of blood cells responsible for blood clotting (platelets) - a reaction known as heparin-induced thrombocytopenia - within the last 100 days or if there are antibodies against enoxaparin in the patient's blood.
• If the patient has severe bleeding or a medical condition associated with an increased risk of bleeding (such as stomach ulcers, recent brain or eye surgery), including recent hemorrhagic stroke.
• If the patient is using Crusia to treat blood clots and spinal or epidural anesthesia or lumbar puncture is planned within 24 hours.

Warnings and precautions

Crusia should not be used interchangeably with other low molecular weight heparins. This is because they are not identical and differ in activity and instructions for use.
Before starting to use Crusia, you should discuss this with your doctor or pharmacist if:

• the patient has ever had a reaction to heparin that caused a significant decrease in the number of platelets
• the patient is scheduled to have spinal or epidural anesthesia or lumbar puncture (see "Surgical procedures and anesthetics"): an appropriate time interval should be allowed between the use of Crusia and this procedure
• the patient has a heart valve replacement
• the patient has endocarditis (infection of the membrane lining the heart)
• the patient has had stomach ulcers
• the patient has recently had a stroke
• the patient has high blood pressure
• the patient has diabetes or has problems with blood vessels in the eyes caused by diabetes (so-called diabetic retinopathy)
• the patient has recently had eye or brain surgery
• the patient is elderly (over 65 years), especially if they are over 75 years old
• the patient has kidney disease
• the patient has liver disease
• the patient is underweight or overweight
• the patient has an increased level of potassium in the blood (which can be checked with a blood test)
• the patient is currently taking medications that may cause bleeding (see below "Crusia and other medicines")

Before starting to use this medicine and periodically during its use, the patient may undergo a blood test to check the number of platelets in the blood and the level of potassium.

Children and adolescents:

The safety and efficacy of enoxaparin have not been evaluated in children and adolescents.

Crusia and other medicines

You should tell your doctor or pharmacist about all the medicines you are currently taking or have recently taken, as well as any medicines you plan to take.

• Warfarin - a medicine used to thin the blood
• Aspirin (also known as acetylsalicylic acid or ASA), clopidogrel, or other medicines used to prevent blood clots (see also section 3 "Change of anticoagulant medicine")
• Dextran injections - used as a blood substitute
• Ibuprofen, diclofenac, ketorolac, or other non-steroidal anti-inflammatory medicines used to treat pain and swelling in arthritis and other conditions
• Prednisolone, dexamethasone, or other medicines used to treat asthma, rheumatoid arthritis, and other conditions
• Medicines that increase the level of potassium in the blood, such as potassium salts, diuretics, and certain heart medicines.

Surgical procedures and anesthetics

If the patient is scheduled to have a lumbar puncture or surgery under spinal or epidural anesthesia, they should inform their doctor that they are using Crusia. See "When not to use Crusia". Additionally, the patient should inform their doctor if they have any spinal problems or if they have had spinal surgery.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before using this medicine.
In pregnant women with a mechanical heart valve, there may be an increased risk of blood clots. The doctor should discuss this with the patient.
Women who are breastfeeding or plan to breastfeed should consult their doctor before using this medicine.

Driving and using machines

Crusia does not affect the ability to drive or use machines.
The doctor should document the trade name and batch number of the product used.

Crusia contains sodium

This medicine contains less than 1 mmol (23 mg) of sodium per dose, which means it is essentially "sodium-free".

3. How to use Crusia

This medicine should always be used exactly as prescribed by your doctor or pharmacist. If you are unsure, you should ask your doctor or pharmacist.

Taking the medicine

• Crusia will usually be given to the patient by a doctor or nurse. This is because it requires injection.
• After returning home, the patient may need to continue using Crusia and inject it themselves (see the injection instructions below).

below.

• Crusia is usually given as a subcutaneous injection.
• Crusia may be given as an intravenous injection after certain types of heart attack or after surgery.
• Crusia may be introduced into the dialyzer tubing that returns blood to the body (the so-called arterial line) at the start of the dialysis session. Crusia should not be given as an intramuscular injection.

Dose

• The doctor will decide what dose of Crusia the patient should take. This depends on the reason for using the medicine.
• In patients with kidney disease, the patient may receive a lower dose of Crusia.
• 1. Treatment of blood clots in the patient's blood
• The usual dose is 150 IU (1.5 mg) per kilogram of body weight once daily or 100 IU (1 mg) per kilogram of body weight twice daily.
• The doctor will decide how long the patient should receive Crusia.
• 2. Prevention of blood clot formation in the patient's blood in the following situations:
• Surgery or limited mobility due to illness
• The dose depends on the patient's risk of developing a blood clot. The patient will receive Crusia at a dose of 2000 IU (20 mg) or 4000 IU (40 mg) per day.
• In the case of planned surgery, the first injection is usually given 2 hours or 12 hours before the operation.
• If the patient has limited mobility due to illness, they will usually receive Crusia at a dose of 4000 IU (40 mg) per day.
• The doctor will decide how long the patient should receive Crusia.
• After a heart attackCrusia can be used in two different types of heart attack: heart attack with ST-segment elevation (STEMI) and heart attack without ST-segment elevation (NSTEMI). The dose of Crusia will depend on the patient's age and the type of heart attack they had.

Non-ST-segment elevation myocardial infarction (NSTEMI):

• The usual dose of Crusia is 100 IU (1 mg) per kilogram of body weight every 12 hours.
• The doctor will usually recommend that the patient also take aspirin (acetylsalicylic acid).
• The doctor will decide how long the patient should receive Crusia.

ST-segment elevation myocardial infarction (STEMI) in patients under 75 years of age:

• The initial dose of Crusia is 3000 IU (30 mg) given as an intravenous injection.
• Crusia is also given as a subcutaneous injection. The usual dose is 100 IU (1 mg) per kilogram of body weight every 12 hours.
• The doctor will usually recommend that the patient also take aspirin (acetylsalicylic acid).
• The doctor will decide how long the patient should receive Crusia.

ST-segment elevation myocardial infarction (STEMI) in patients 75 years of age or older:

• The usual dose is 75 IU (0.75 mg) per kilogram of body weight every 12 hours.

12 hours.

• The maximum dose of Crusia in the first two doses is 7500 IU (75 mg).
• The doctor will decide how long the patient should receive Crusia.

Patient undergoing percutaneous coronary intervention (PCI):
Depending on when the last dose of Crusia was given, the doctor may decide to give an additional dose of Crusia before the PCI procedure.
Crusia will be given as an intravenous injection.

• 3. Prevention of blood clot formation in the dialyzer tubing
• The usual dose is 100 IU (1 mg) per kilogram of body weight.
• Crusia is injected into the tubing that returns blood to the body (the so-called arterial line) at the start of the dialysis session. This dose is usually sufficient for a 4-hour dialysis session. However, if necessary, the doctor may give the patient an additional dose of 50 IU to 100 IU (0.5 to 1 mg) per kilogram of body weight.

Instructions for using the pre-filled syringe

Self-injection of Crusia

If the patient is able to inject themselves with Crusia, the doctor or nurse will show them how to do it. Do not attempt to inject yourself without instruction.
If the patient is unsure what to do, they should talk to their doctor or nurse immediately. Proper injection technique (called "subcutaneous injection") will help reduce pain and bruising at the injection site.

Before self-injecting Crusia

• Gather the necessary items: syringe, cotton ball, or soap and water, and a container for sharp objects.
• Check the expiration date on the packaging. Do not use the medicine after the expiration date.
• Check if the syringe is damaged and if the liquid is clear. If not, use another syringe.
• Make sure what dose is to be injected.
• Examine the abdomen to check if the last injection caused redness, discoloration, swelling, drainage, or if it is still painful. If so, consult a doctor or nurse.

Instructions for self-injecting Crusia:

(Instructions for pre-filled syringes without a safety device)

Preparing the injection site

• 1) Choose an injection site on the right or left side of the abdomen. The injection site should be at least 5 cm away from the navel towards the sides.
• Do not inject within 5 cm of the navel or around existing scars or bruises.
• Change the injection site between the left and right side of the abdomen, depending on the site of the previous injection.

• 2) Wash your hands. Clean (do not rub) the injection site with a cotton ball soaked in alcohol or soap and water.
• 3) Sit or lie down in a comfortable position, so you are relaxed. Make sure the injection site is in your line of sight. A chair, couch, or bed with pillows for support will be suitable.

Choosing the dose

• 1) Carefully remove the needle cap from the syringe. Discard the cap.
• Do not press the plunger before injecting to remove air bubbles. This may reduce the dose administered.
• After removing the cap, do not touch the needle. This will ensure the sterility of the needle.

• 2) If the amount of medicine in the syringe is the same as the prescribed dose, there is no need to adjust the dose. You can now inject.
• 3) If the dose depends on body weight, it may be necessary to adjust the dose in the syringe according to the prescribed dose. In this case, excess medicine should be discarded, holding the syringe with the needle facing down (to keep air bubbles in the syringe) and discard the excess medicine into a container.
• 4) A drop may appear at the tip of the needle. If this happens, the drop should be removed before injecting by tapping the syringe with the needle facing down. You can now inject.

Injecting

• 1) Hold the syringe in the hand you write with (like a pencil). With the other hand, gently grasp the cleaned skin of the abdomen with your index finger and thumb, creating a fold of skin between your fingers.
• Make sure to maintain the skin fold while injecting.
• 2) Hold the syringe with the needle facing down (at a 90-degree angle). Insert the entire length of the needle into the skin fold.

• 3) Press the plunger with your thumb. This will inject the medicine into the abdominal fat. You should inject the entire amount of medicine from the syringe.
• 4) Remove the needle from the injection site, pulling it out straight. Keep the needle away from yourself and others. Now you can release the skin fold.

After injecting

• 1) To avoid bruising, do not rub the injection site after injecting.
• 2) Dispose of the used syringe in a container for sharp objects. Close the container and store it in a place that is out of sight and reach of children. If the container is full, dispose of it according to the doctor's or pharmacist's instructions.

Any unused medicines or waste materials should be disposed of in accordance with local regulations.
In case of feeling that the dose is too strong (for example, unexpected bleeding occurs) or too weak (for example, the dose probably does not work), you should consult a doctor or pharmacist.

Instructions for pre-filled syringes with a safety device:

Preparing the injection site

• 1) Choose an injection site on the right or left side of the abdomen. The injection site should be at least 5 cm away from the navel towards the sides.
• Do not inject within 5 cm of the navel or around existing scars or bruises.
• Change the injection site between the left and right side of the abdomen, depending on the site of the previous injection.

• 2) Wash your hands. Clean (do not rub) the injection site with a cotton ball soaked in alcohol or soap and water.
• 3) Sit or lie down in a comfortable position, so you are relaxed. Make sure the injection site is in your line of sight. A chair, couch, or bed with pillows for support will be suitable.

Choosing the dose

• 1) Carefully remove the needle cap from the syringe. Discard the cap.
• Do not press the plunger before injecting to remove air bubbles. This may reduce the dose administered.
• After removing the cap, do not touch the needle. This will ensure the sterility of the needle.

• 2) If the amount of medicine in the syringe is the same as the prescribed dose, there is no need to adjust the dose. You can now inject.
• 3) If the dose depends on body weight, it may be necessary to adjust the dose in the syringe according to the prescribed dose. In this case, excess medicine should be discarded, holding the syringe with the needle facing down (to keep air bubbles in the syringe) and discard the excess medicine into a container.
• 4) A drop may appear at the tip of the needle. If this happens, the drop should be removed before injecting by tapping the syringe with the needle facing down. You can now inject.

Injecting

• 1) Hold the syringe in the hand you write with (like a pencil). With the other hand, gently grasp the cleaned skin of the abdomen with your index finger and thumb, creating a fold of skin between your fingers.
• Make sure to maintain the skin fold while injecting.
• 2) Hold the syringe with the needle facing down (at a 90-degree angle). Insert the entire length of the needle into the skin fold.

• 3) Press the plunger with your thumb. This will inject the medicine into the abdominal fat. You should inject the entire amount of medicine from the syringe.
• 4) Remove the needle from the injection site, pulling it out straight while still holding the plunger. Keep the needle away from yourself and others. The safety device is activated by firmly pressing the plunger. The protective cover will automatically cover the needle and a clicking sound will be heard, confirming the activation of the protective cover. Now you can release the skin fold.

After injecting

• 1) To avoid bruising, do not rub the injection site after injecting.
• 2) Dispose of the used syringe in a container for sharp objects. Close the container and store it in a place that is out of sight and reach of children. If the container is full, dispose of it according to the doctor's or pharmacist's instructions.

Any unused medicines or waste materials should be disposed of in accordance with local regulations.
In case of feeling that the dose is too strong (for example, unexpected bleeding occurs) or too weak (for example, the dose probably does not work), you should consult a doctor or pharmacist.

Change of anticoagulant medicine

• Change from Crusia to medicines that thin the blood, called vitamin K antagonists (e.g. warfarin)The doctor will recommend blood tests to determine the INR (International Normalized Ratio) and based on this, will inform the patient when to stop taking Crusia.
• Change from vitamin K antagonists (e.g. warfarin) to CrusiaThe patient should stop taking the vitamin K antagonist. The doctor will recommend blood tests to determine the INR and based on this, will inform the patient when to start taking Crusia.
• Change from Crusia to direct oral anticoagulantsThe patient should stop taking Crusia. Then, the patient should start taking the direct oral anticoagulant 0-2 hours before the scheduled time of the next injection; and then continue taking the medicine as usual.
• Change from direct oral anticoagulant to CrusiaThe patient should stop taking the direct oral anticoagulant. Treatment with Crusia can be started 12 hours after the last dose of the direct oral anticoagulant.

Use of a higher than recommended dose of Crusia

If the patient thinks they have used too much or too little Crusia, they should immediately inform their doctor, nurse, or pharmacist, even if they do not notice any problems. In case of accidental injection or ingestion of Crusia by a child, immediate medical attention should be sought.

Missing a dose of Crusia

If a dose is missed, it should be taken as soon as possible. Do not take a double dose to make up for a missed dose. Keeping a diary can help ensure that no dose is missed.

Stopping the use of Crusia

If the patient has any further questions about the use of this medicine, they should ask their doctor, pharmacist, or nurse.
It is important to continue injecting Crusia until the doctor recommends stopping it. If treatment is stopped, a blood clot may form, which can be very dangerous.

4. Possible side effects

Like all medicines, Crusia can cause side effects, although not everybody gets them.
As with other similar medicines (used to reduce blood clotting), Crusia can cause bleeding, which can be life-threatening. In some cases, bleeding may not be immediately visible.
If the patient experiences any bleeding that does not stop on its own, as well as signs of excessive bleeding (severe weakness, fatigue, paleness, dizziness, headaches, or unexplained sweating), they should immediately consult their doctor. The doctor may decide to monitor the patient more closely or change the medicine.
If the patient experiences any of the following symptoms, they should stop using enoxaparin and seek medical help immediately:

• Any symptoms of a severe allergic reaction (such as difficulty breathing, swelling of the lips, mouth, throat, or eyes).
• A red, scaly, widespread rash with thickening of the skin and blisters, accompanied by fever.

The patient should immediately consult their doctor:

• If they experience any signs of a blood clot blocking a blood vessel, such as:
• cramping pain, redness, increased warmth, or swelling in one leg - these are symptoms of deep vein thrombosis
• shortness of breath, chest pain, fainting, or coughing up blood - these are symptoms of pulmonary embolism
• If the patient experiences painful bruising or purple spots under the skin that do not fade when pressed. The doctor may order blood tests to check the number of platelets in the blood.

Summary of possible side effects:

Very common (may affect more than 1 in 10 people)

• Bleeding.
• Increased liver enzyme activity.

Common (may affect up to 1 in 10 people)

• Increased tendency to bruise. This may be due to a decrease in the number of platelets.
• Purple spots on the skin. These changes are more likely to occur at the injection sites of Crusia.
• Hives (nettle rash).
• Itching, redness of the skin.
• Bruising or pain at the injection site.
• Decreased number of red blood cells.
• Increased number of platelets.
• Headaches.

Uncommon (may affect up to 1 in 100 people)

• Sudden severe headache. This may be a sign of bleeding in the brain.
• Tenderness and swelling of the abdomen. This may be a sign of bleeding in the stomach.
• Large, red, irregularly-shaped skin changes with blisters or without blisters.
• Skin irritation (local irritation).
• The patient may notice yellowing of the skin or eyes and darker urine. This may indicate liver disease.

Rare (may affect up to 1 in 1,000 people)

• Severe allergic reaction. Symptoms of such a reaction may include: rash, difficulty swallowing or breathing, swelling of the lips, face, throat, or tongue.
• High level of potassium in the blood. This is more likely to occur in people with kidney disease or diabetes. The doctor may check this with a blood test.
• High level of eosinophils in the blood. The doctor may check this with a blood test.
• Hair loss.
• Osteoporosis (a condition in which bones are more prone to fractures) after long-term use of the medicine.
• Numbness, tingling, and muscle weakness (especially in the lower part of the body) after lumbar puncture or spinal or epidural anesthesia.
• Loss of control over the bladder or bowels (a condition in which the patient is unable to control when they need to go to the toilet).
• Hardening or a lump at the injection site.

Reporting side effects

If the patient experiences any side effects, including those not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.

5. How to store Crusia

Store in a temperature below 25°C. Do not freeze.
Crusia pre-filled syringes are single-dose containers - any unused medicine should be discarded.
The medicine should be stored in a place that is out of sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging. The expiration date refers to the last day of the month stated.
Do not use the medicine if the pre-filled syringe is damaged or if the product is not clear.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Crusia contains

• The active substance of Crusia is enoxaparin sodium.

Each pre-filled syringe contains enoxaparin sodium equivalent to 2000 IU of anti-Xa activity (which is equivalent to 20 mg) in 0.2 ml of water for injection.
Each pre-filled syringe contains enoxaparin sodium equivalent to 4000 IU of anti-Xa activity (which is equivalent to 40 mg) in 0.4 ml of water for injection.
Each pre-filled syringe contains enoxaparin sodium equivalent to 6000 IU of anti-Xa activity (which is equivalent to 60 mg) in 0.6 ml of water for injection.
Each pre-filled syringe contains enoxaparin sodium equivalent to 8000 IU of anti-Xa activity (which is equivalent to 80 mg) in 0.8 ml of water for injection.
Each pre-filled syringe contains enoxaparin sodium equivalent to 10,000 IU of anti-Xa activity (which is equivalent to 100 mg) in 1.0 ml of water for injection.

• The other ingredient is water for injection.

What Crusia looks like and contents of the pack

Crusia is a clear, colorless to pale yellow solution for injection in a pre-filled syringe made of glass type I with a rubber stopper, plunger, and needle in a protective sleeve, with or without an automatic safety device. It is available in the following strengths:
Crusia 2000 IU (20 mg)/0.2 ml solution for injection in a 0.5 ml pre-filled syringe without graduation.
Pack sizes: 2, 6, 10, 20, and 50 pre-filled syringes.
Crusia 4000 IU (40 mg)/0.4 ml solution for injection in a 0.5 ml pre-filled syringe without graduation.
Pack sizes: 2, 6, 10, 20, 30, and 50 pre-filled syringes.
Crusia 6000 IU (60 mg)/0.6 ml solution for injection in a 1 ml pre-filled syringe.
Pack sizes: 2, 6, 10, 12, 24, 30, and 50 pre-filled syringes.
Crusia 8000 IU (80 mg)/0.8 ml solution for injection in a 1 ml pre-filled syringe.
Pack sizes: 2, 6, 10, 12, 24, 30, and 50 pre-filled syringes.
Crusia 10,000 IU (100 mg)/1 ml solution for injection in a 1 ml pre-filled syringe.
Pack sizes: 2, 6, 10, 12, 24, 30, and 50 pre-filled syringes.
Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer:

Marketing authorization holder:
Laboratorios Farmacéuticos Rovi, S.A.
Julián Camarillo, 35
28037 Madrid
Spain
tel.: (+48) 699 711 147
Manufacturer:
ROVI Pharma Industrial Services S.A.
Julián Camarillo, 35
28037 Madrid
Spain

This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Austria, Denmark, Finland, Netherlands, Germany, Norway, Sweden, United Kingdom (Northern Ireland), Spain, Portugal, Greece, Bulgaria, Czech Republic, Estonia, Croatia, Hungary, Latvia, Poland, Romania, Slovakia: Crusia
France: Enoxaparine Crusia
Italy: Rovinadil
Belgium, Ireland, Slovenia, Luxembourg: Teuro

Date of last revision of the leaflet: 01/2023

Other sources of information

Detailed information on this medicine is available on the website of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: http://www.urpl.gov.pl/